Nuvectis (NVCT) VP Finance Michael J. Carson Receives Award

What Happened
Michael J. Carson, Vice President, Finance of Nuvectis Pharma (NVCT), received a grant of 30,000 restricted common shares on August 3, 2026. The award was reported at a $0.00 acquisition price (no cash paid) and thus shows $0 immediate purchase value. The shares are compensatory restricted stock rather than an open-market buy or sale.

Key Details

• Transaction date and type: 2026-08-03 — Award/Grant (Code A) of 30,000 restricted shares at $0.00.
• Total reported value at grant: $0 (compensatory restricted stock).
• Vesting: The 30,000 restricted shares will fully vest on August 3, 2027, subject to Mr. Carson’s continued service (Footnote F1).
• Footnote: F2 indicates these are shares of restricted common stock.
• Shares owned after transaction: Not reported in the filing.
• Filing date: Form 4 filed 2026-08-05; filing does not indicate lateness.

Context
Restricted stock awards are compensation tied to continued service or performance and do not represent an immediate market purchase or sale. Because the shares vest one year later (subject to service), this is primarily a retention/compensation action rather than an immediate liquidity or market-confidence signal.